Τετάρτη 11 Ιανουαρίου 2012
The EU generics market: a Greek perspective
Rebecca Aris interviews Deepak Murpani, VP Product Development Genepharm
Ahead of his speaking engagement at the Generics & Biosimilars summit 2012, Deepak Murpani shares his insights into the current state of the generics industry and how he thinks it will evolve in the future. He also offers his insights on the impact that the downturn of the Greek economy has had on generics.
Read the interview summary
Με απόφαση του ΙΣΑ οι ιδιώτες γιατροί συνεχίζουν την αποχή τους
Την συνέχιση των απεργιακών κινητοποιήσεων, ως την Παρασκευή 13 Ιανουαρίου, αποφάσισε το Διοικητικό Συμβούλιο του Ιατρικού Συλλόγου Αθήνας. «Ο ΙΣΑ συνεχίζει τον αγώνα για τη δημιουργία ενός βιώσιμου και ισχυρού Ενιαίου Οργανισμού Παροχής Υπηρεσιών Υγείας (ΕΟΠΥΥ), που θα προσφέρει υψηλές υπηρεσίες υγείας στους ασφαλισμένους, με σεβασμό στον λειτουργό της υγείας», τονίζουν οι εκπρόσωποι των γιατρών.
Συγκεκριμένα, οι εκπρόσωποι του ΙΣΑ ζητούν την άμεση καταβολή στους συμβεβλημένους γιατρούς του ΟΠΑΔ οφειλές ύψους 350 εκατομμυρίων ευρώ. Επίσης, διεκδικούν 20 ευρώ ως αμοιβή κατά πράξη και περίπτωση, που αποτελεί το ελάχιστο ποσό αμοιβής του ευρωπαίου γιατρού, για την ιατρική του πράξη, και ζητούν διευκρινίσεις σε ότι αφορά την ελεύθερη συνταγογράφηση και εκείνων των γιατρών που δεν είναι συμβεβλημένοι με τον ΕΟΠΥΥ.
GlaxoSmithKline has announced the launch of MyAsthma - a New Dimension in Asthma Control
GlaxoSmithKline has announced the launch of MyAsthma, the UK's first, free personalised health application (app) designed to help people over the age of 12 take greater control of their asthma. The app features the Asthma Control Test™ (ACT), a simple 30-second test developed by leading asthma experts, which gives asthma patients a useful measure of their asthma control in an easy-to-understand score. Although many patients are receiving treatment for their asthma, a recent survey in the UK shows that almost 50% do not have their asthma under control. MyAsthma applies new technology to traditional asthma management to provide a daily personalised plan helping patients to manage their asthma more effectively.
"MyAsthma is exciting for people with asthma as it uses new technology to help them better understand and control this chronic disease. MyAsthma can also be used by carers of people with asthma, especially parents and is a great way to teach older children the importance of taking control of their asthma. This creates a habit that they can carry into adulthood, a significant and positive step for the future of asthma care in the UK" said Dr Mike Thomas, Asthma UK Senior Research Fellow with the University of Aberdeen and Chief Medical Adviser, Asthma UK. "Empowering patients to take more control of long-term conditions not only leads to improved health outcomes but also cost savings."
Asthma is a chronic condition of the airways with symptoms including breathing difficulties and sudden episodes of breathlessness. Asthma affects approximately 5.4 million people in the UK with 4.3m adults and 1.1m children, currently receiving treatment for mild, moderate or severe asthma.(3) When not well controlled, asthma symptoms can result in hospitalisation, even fatality. Asthma places a significant economic burden on both individuals and society. The NHS spends around £1 billion a year treating and caring for people with asthma and between 2008 and 2009, up to 1.1 million working days were lost due to breathing or lung problems.
Designed with the support of a panel of asthma experts and Professor Rob Horne, a behavioural psychologist at the University of London, MyAsthma displays localised information on asthma triggers such as pollen count, pollution and weather. It is enabled to help patients track their symptoms and ACT score evolution over time and contains a library with useful information about asthma. An algorithm generates tailored messages, based on a person's ACT score and individual profiles, to help people address the personal barriers they face and to help them improve their management of the condition. MyAsthma is convenient and easy to use allowing patients to track their asthma control at the quick touch of a smartphone screen, which can help to create a more informed dialogue during consultations with their healthcare professional. (See the video).
Medtronic launches new remote glucose monitor
Medtronic has introduced a new type of remote glucose monitor that allows parents and caregivers to keep track of patients' blood sugar levels from a different room.
The new mySentry device has been approved by the US Food and Drug Administration and works in conjunction with the MiniMed Paradigm Real-Time Revel System.
It allows carers to track real-time insulin pump status and glucose trends, as well as hearing alerts and alarms, at their bedside, while diabetes sufferers remain in their own rooms.
This will help to minimise the number of severe hypoglycaemia incidents that typically take place during the night, providing peace of mind for caregivers while enhancing care quality for the patients themselves.
Greg Meehan, vice-president and general manager of the continuous glucose monitoring business at Medtronic, said it will "help people more proactively manage their diabetes by making it easier and more convenient to access the wealth of information captured by our integrated insulin pump and continuous glucose monitoring system".
Last month, the company published new data from a study showing the benefits its AdaptiveStim with RestoreSensor neurostimulation system can offer to chronic pain patients.
New service offers free and easy-to-use information on patient safety issues
Quintiles is promoting the benefits of its MediGuard healthcare information management system to former users of the now defunct Google Health. Quintiles' digital health unit was launched earlier this week with the aim of better supporting its MediGuard and ClinicalResearch online patient communities.
The new service allows users to securely store information about their own medicine use in order to identify any possible dangerous drug interactions and safety alerts, as well as sharing feedback with fellow patients on side effects and similar issues.
An open invitation to join MediGuard has been extended to patients who used Google Health prior to its January 1st 2012 discontinuation, with Google stating that the service had failed to achieve its targets in terms of scale.
David Coman, senior vice-president at Quintiles and head of the digital patient unit, said MediGuard, with its 2.5 million members, is successfully executing Google's intended model, offering free and easy-to-use information on patient safety issues.
Mr Coman said: "Google Health was a brilliant concept, but in order for online patient services to work, there must be a clear benefit to patients who enroll in them."
Εγγραφή σε:
Αναρτήσεις (Atom)